⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 12, 2024Open Access

Supplementary Figure 5 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Alana L. Keller Lauren T. Reiman Olivia Perez de Sarah E. Parzych Peter A. Forsberg Peter Kim Kamlesh Bisht Hongfang Wang Helgi van de Velde Daniel W. Sherbenou

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The percentage of MM cells CD28+ does not appear to affect sensitivity to SAR442257

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keller et al. (2024) studied this question.

synapsesocial.com/papers/68e746dfb6db6435876c00b3 https://doi.org/10.1158/2767-9764.25392852.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
2Supplementary Figure 4 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
3Supplementary Figure 4 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
4Supplementary Figure 2 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
5Supplementary Figure 2 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
6Supplementary Figure 3 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
7Supplementary Figure 3 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024
8Supplementary Figure 1 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies2024